# Patent

## Title
Determination of in vivo DNA double-strand break localization and application thereof

## Abstract

The present invention relates to a method for determining the in vivo localization of double-strand breaks in a host cell, comprising incubating a host cell suspected to comprise DNA double-strand breaks and a linear polynucleotide comprising a known sequence, detecting the in vivo insertion sites of said polynucleotide in the genome of said host cell, and assessing the in vivo localization of double-strand breaks. Further envisaged by the present invention is a method for obtaining an endonuclease with altered in vivo specificity. Finally, the present invention is directed to a kit for determining in vivo specificity of an endonuclease.

## Background
SEQUENCE LISTING
The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is herein incorporated by reference in its entirety.
The DNA repair machinery of live cells will seek to repair double strand breaks (DSBs) by homologous recombination (HR) ad integrum or by the more error-prone non-homologous end joining (NHEJ) pathway that essentially religates whatever sequence is available to the open remaining DNA strands. Spontaneous HR is a very rare event in mammalian cells with approximately 1 donor DNA recombination per 106 cells (Cathomen and Joung 2008). This rate increases drastically when cells are exposed to agents that induce DSBs, like e.g. ionizing radiation; also, introduction of DSB by ZFN has been shown to potentiate the likelihood of HR at the cleavage site by a factor of 100-10000 (Durai et al. 2005; Porteus and Carroll 2005), making artificial ZFN a promising tool for genetic manipulation of live cells, including clinical therapy. DSB get repaired quickly, leaving no or only minor nucleotide changes or deletions in the genome, so it has been difficult to obtain data relating to the localization and/or frequency of double-strand breaks occurring in the genome of a cell.
Zinc finger nucleases (ZFNs) are artificial restriction enzymes comprising a zinc finger DNA-binding domain fused to a DNA-cleavage domain. ZFNs are designed to introduce DSBs at virtually any selected genome position. To achieve site-specific genome targeting, ZFNs combine unspecific Fok I endonuclease cleavage domains with arbitrary chosen binding domains of zinc finger proteins (ZFPs). Thereby, ZFN function requires the dimerization of a specific ZFN monomer binding upstream to the target site on the plus strand with a second ZFN-monomer that binds downstream of the target site (Kim et al. 1996; Mani et al. 2005). To reduce cytotoxicity of ZFN, mainly caused by homodimer formation of identical ZFN monomers at off-target sites, a new generation of ZFN has been developed by introducing complementary substitutions of single amino acids in the nuclease domain preventing homodimerization of the Fokl subunits (Miller et al. 2007; Szczepek et al. 2007).
Therapeutic applications of ZFN comprise three main categories of DNA modifications in live cells: i) targeted mutagenesis (gene knock-out), inducing loss of information during NHEJ, ii) gene correction at the target locus by HR involving a homologous donor DNA fragment and iii) targeted integration of an expression cassette by HR into a potentially “safe harbor” sequence whose mutation should be harmless for the targeted cell type. The mode of transfer of ZFN into cells is highly relevant for the success rate and toxicity of specific DNA modification in live cells. It was previously demonstrated that the delivery of ZFN into cells via non-integrating integrase-defective lentiviral vectors (IDLV) has little or no acute cytotoxicity, achieves transfer of the ZFN cDNA into almost every target cell, and has the potential to achieve HR mediated editing of the genome sequence specifically in up to 50% of the transduced cell populations (Lombardo et al. 2007). However, because DSB get repaired quickly, leaving no or only minor nucleotide changes or deletions in the genome, no definitive data has been available neither on the nature nor on the frequency of “off-site” DSB caused by ZFN activity outside of the intended target sequence. This remains an important open issue in using ZFN technology, not least if its application is intended for clinical gene therapy, since the availability of specific genomic editing would minimize or abolish the risk of insertional mutagenesis and oncogenesis observed in preclinical studies and clinical trials with retroviral vectors (Hacein-Bey-Abina et al. 2003; Modlich et al. 2006; Montini et al. 2006; Ott et al. 2006; Hacein-Bey-Abina et al. 2008; Howe et al. 2008).
Thus, means and methods are required for complying with the aforementioned needs. The said technical problem is solved by the embodiments characterized in the claims and herein below.
Accordingly, the present invention relates to a method for determining the in vivo localization of double-strand breaks in a host cell, comprising a) incubating said host cell suspected to comprise DNA double-strand breaks and a linear polynucleotide comprising a known sequence, b) detecting the in vivo insertion sites of said polynucleotide in the genome of said host cell, c) determining the in vivo positions of double-strand breaks, and d) assessing the in vivo localization of double-strand breaks.
The term “DNA double-strand break” or “double-strand break” is understood by the skilled artisan.
The term “determining the in vivo localization of double-strand breaks”, preferably, relates to determining the positions in the genome of a host cell of double-strand breaks occurring in said host cell. It is to be understood that determining the localization of double-strand breaks according to the current specification includes the repair of said double-strand breaks, i.e. the double-strand breaks do no longer exist by the times their position is determined. It is further to be understood that the determination of the in vivo localization of double-strand breaks does not determine the exact position in the genome where the double-strand break occurred. However, the term requires that the position determined is within 10, 25, 50, 100, 250, 500, 1000, 2500, or 5000 nucleotides from the position where the double-strand break occurred for at least 75%, 85%, 90%, 95%, 97%, or 99% of the double-strand breaks examined.
As used herein, the term “incubating” relates to maintaining host cells under controlled conditions favorable for maintenance and/or growth of said host cells, preferably in an incubator. It is, however, also contemplated by the current invention that the host cells are comprised in a tissue or an organism.
The term “host cell” relates to a cell comprising the components required for at least one of the DNA repair systems mediating double strand break repair by homologous recombination ad integrum (HR) or by non-homologous end joining (NHEJ). Preferably, the host cell is a eukaryotic cell, more preferably a mammalian cell, even more preferably a human cell, and most preferably the host cell is a K562 cell. Preferably, the host cell is a cell originating from an organism whose genome has been completely sequenced.
The terms “linear polynucleotide comprising a known sequence” or “linear polynucleotide”, preferably, relate to a polynucleotide comprising at least one stretch of nucleotides with a known nucleotide sequence. Preferably, said stretch is at least 18, at least 19, at least 20, at least 25, or at least 50 nucleotides long. Preferably, the nucleotide sequence of the linear polynucleotide is known in its entirety.
It is also contemplated by the current invention that the linear polynucleotide comprises additional sequences. Preferably, said additional sequences code for an integrase-deficient lentivirus, comprising, preferably, an expressible gene for a selectable marker, like, e.g. hygromycin phosphotransferase (Hygromycin B kinase, EC 2.7.1.119) or neomycin-kanamycin phosphotransferase (Kanamycin kinase, EC 2.7.1.95). Preferably, the endonuclease is comprised in said linear polynucleotide in an expressible form.
As used herein, the term “in vivo insertion sites”, preferably, relates to the positions in the genome of a host cell wherein copies of the linear polynucleotide are covalently integrated by means of the cellular HR or the NHEJ systems. It is to be understood that not every DSB induced by an endonuclease and repaired by cellular systems in the presence of a linear polynucleotide will lead to the covalent integration of said linear polynucleotide. However, the term requires that in a given population of host cells used for the determination according to this specification, the number of insertion events is high enough to permit a statistical analysis of the insertion sites. Preferably, at least 50, at least 75, at least 85, at least 90, at least 100, or at least 250 insertion events are analyzed.
The term “in vivo positions of double-strand breaks”, preferably relates to positions in the genome of a host cell where at least one double-strand break occurred.
As used herein, the term “determining the in vivo positions of double-strand breaks” relates to establishing the positions in the genome of a host cell where at least one double-strand break occurred. Preferably, determining the in vivo positions of double-strand breaks comprises the following steps: i) amplifying genomic regions comprising insertion sites. Preferably, amplification is achieved by PCR, more preferably by Linear Amplification Mediated PCR (LAM-PCR, WO/2000/024929), using the information on the known nucleotide sequence comprised in the linear polynucleotide to design specific primers for PCR amplification; ii) Sequencing the amplified polynucleotides obtained in step i); and iii) allocating insertion sites to positions of double-strand breaks.
As used in the current specification, the term “endonuclease” relates to an enzyme hydrolysing phosphodiester bonds within a polynucleotide. Preferably, both strands of DNA are hydrolysed. More preferably, the hydrolysis sites of opposing strands are separated by not more than 100, 50, 25, 20, 15, 10 nucleotides, such that one of the cellular DSB repair systems acts on the ends generated by said hydrolysis. Preferably, the hydrolysis sites are located at a distance of not more than 50, 100, 250, 500, 1000, 2000, 5000, or 10000 nucleotides from the recognition site of the endonuclease. More preferably, the endonuclease is a homing endonuclease or a type I restriction endonuclease. Most preferably, the endonuclease is a Zinc finger endonuclease (ZFN), comprising an endonuclease domain, e.g. the non-specific DNA cleavage domain of the Fokl restriction endonuclease (Kim et al. 1996; Mani et al. 2005), and a DNA binding domain comprising at least one, at least two, or at least three zinc finger domains.
The definitions made above apply mutatis mutandis to the following:
In a further preferred embodiment, the current invention relates to a method for determining the in vivo specificity of an endonuclease, comprising a) incubating a host cell comprising said endonuclease and a linear polynucleotide comprising a known sequence, b) detecting the in vivo insertion sites of said polynucleotide in the genome of said host cell, c) determining the in vivo recognition sites of said endonuclease, and d) assessing the in vivo specificity of said endonuclease.
The term “determining the in vivo specificity” relates to determining the relative number of recognition sites 100% identical with the known recognition site of an endonuclease leading to the insertion of a linear polynucleotide as compared to the total number of insertion sites determined. It is, however, also contemplated by the current specification that for each recognition site identified the similarity to the known recognition site of the endonuclease is determined, so that a consensus sequence can be calculated. A person skilled in the art knows how to obtain an endonuclease with a known recognition site. This is e.g. accomplished by testing the hydrolytic activity of an endonuclease in the presence of various oligo- and/or polynucleotides. Also, e.g. an endonuclease with a known recognition site can be selected, e.g. by phage display. It is, however, also contemplated by the current invention that the known recognition site is e.g. generated by modularly assembling zinc-finger domains of known specificity.
The term “recognition site” relates to sequences in the genome of a host cell bound by the endonuclease of the current specification. Preferably, the binding of a ZFN is mediated by the at least on zinc finger domain interacting with the nucleotides of the recognition site.
As used herein, the term “determining the in vivo recognition sites” relates to establishing the recognition sites bound in vivo by the endonuclease of the current specification. Preferably, determining the in vivo recognition sites comprises the following steps: i) amplifying genomic regions comprising insertion sites. Preferably, amplification is achieved by PCR, more preferably by Linear Amplification Mediated PCR (LAM-PCR, WO/2000/024929 which is herewith incorporated by reference with respect to its entire disclosure content), using the information on the known nucleotide sequence comprised in the linear polynucleotide to design specific primers for PCR amplification; ii) Sequencing the amplified polynucleotides obtained in step i); and iii) allocating insertion sites to recognition sites. Preferably, allocation is achieved by bioinformatic methods, comprising identifying sequences comprising the linear polynucleotide of the current invention, determining genomic sequences adjacent to said linear polynuceotide, aligning said genomic sequences to the genome of the host cell, in silico prediction of potential endonuclease binding sites, and identifying potential binding sites in physical proximity to insertion sites.
In a further preferred embodiment, the current invention relates to a method for obtaining an endonuclease with an altered in vivo specificity, comprising a) providing at least one mutant of an endonuclease with a known recognition sequence, b) determining the in vivo specificity of said mutant of an endonuclease by the method of any one of claims 9 to 13, c) comparing the recognition sites recognized by said at least one mutant endonuclease with the recognition sites recognized by the unmodified endonuclease, and d) obtaining an endonuclease with an altered in vivo specificity.
As used in this specification, the term “altered in vivo specificity”, preferably, relates to an in vivo specificity which is different from the in vivo specificity of an unmodified second endonuclease used for comparison. The alteration is an increase or decrease in the relative number of recognition sites 100% identical with the theoretical recognition site of an endonuclease; e.g. the relative number of recognition sites 100% identical with the theoretical recognition site is increased by at least 5%, 10%, 15%, 25%, or 50%. It is, however, also contemplated that the alteration is a change in the consensus sequence determined by the method of the current invention as described above.
A “mutant of an endonuclease” or “mutant endonuclease” as used herein relates to an endonuclease molecule comprising at least one amino acid exchange and/or at least one insertion and/or at least one deletion of at least one amino acid as compared to the unmodified endonuclease, wherein said mutant endonuclease still has the activity of hydrolyzing DNA. Preferably, said mutant endonuclease is obtained by mutagenizing an expressible gene of an endonuclease with a known recognition site.
As used herein, the term “providing at least one mutant of an endonuclease” relates to making available at least one mutant endonuclease in a host cell. Preferably, said at least one mutant endonuclease is made available by expressing a mutagenized gene for an endonuclease in said host cell.
“Comparing the recognition sites” as used herein relates to comparing the in vivo specificity determined for the mutant endonuclease with the in vivo specificity determined for the unmodified endonuclease. Preferably, the altered in vivo specificity is an increased in vivo specificity, meaning an in vivo specificity wherein an increased relative number of recognition sites is 100% identical with the known recognition site. It is, however, also contemplated by the current specification that an increased in vivo specificity means that the consensus sequence determined by the method of the current invention as described above comprises a lower frequency of alternative nucleotides in at feast one position of the consensus sequence.
In a further preferred embodiment, the current invention relates to a kit for determining the in vivo specificity of an endonuclease, comprising a polynucleotide providing a linear form in a host cell and a manual.
The term “kit” as used herein refers to a collection of the aforementioned compounds, means or reagents of the present invention which may or may not be packaged together. The components of the kit may be comprised by separate vials (i.e. as a kit of separate parts) or provided in a single vial. Moreover, it is to be understood that the kit of the present invention is to be used for practising the methods referred to herein above. It is, preferably, envisaged that all components are provided in a ready-to-use manner for practising the methods referred to above. Further, the kit preferably contains instructions for carrying out the said methods. The instructions can be provided by a user's manual in paper- or electronic form. For example, the manual may comprise instructions for interpreting the results obtained when carrying out the aforementioned methods using the kit of the present invention.
LITERATURE


    Altschul, S. F., W. Gish, et al. (1990). “Basic local alignment search tool.” J Mol Biol 215(3): 403-10.
    Cathomen, T. and J. K. Joung (2008). “Zinc-finger nucleases: the next generation emerges.” Mol Ther 16(7): 1200-7.
    Durai, S., M. Mani, et al. (2005). “Zinc finger nucleases: custom-designed molecular scissors for genome engineering of plant and mammalian cells.” Nucleic Acids Res 33(18): 5978-90.
    Gaur, M. and A. D. Leavitt (1998). “Mutations in the human immunodeficiency virus type 1 integrase D,D(35)E motif do not eliminate provirus formation.” J Virol 72(6): 4678-85.
    Gotoh, O. (1982). “An improved algorithm for matching biological sequences.” J Mol Biol 162(3): 705-8.
    Hacein-Bey-Abina, S., A. Garrigue, et al. (2008). “Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1.” J Clin Invest 118(9): 3132-42.
    Hacein-Bey-Abina, S., C. von Kalle, et al. (2003). “A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency.” N Engl J Med 348(3): 255-6.
    Honma, M., M. Izumi, et al. (2003). “Deletion, rearrangement, and gene conversion; genetic consequences of chromosomal double-strand breaks in human cells.” Environ Mol Mutagen 42(4): 288-98.
    Honma, M., M. Sakuraba, et al. (2007). “Non-homologous end-joining for repairing I-Scel-induced DNA double strand breaks in human cells.” DNA Repair (Amst) 6(6): 781-8.
    Howe, S. J., M. R. Mansour, et al. (2008). “Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients.” J Clin Invest 118(9): 3143-50.
    Kent, W. J. (2002). “BLAT—the BLAST-like alignment tool.” Genome Res 12(4): 656-64.
    Kim, Y. G., J. Cha, et al. (1996). “Hybrid restriction enzymes: zinc finger fusions to Fok I cleavage domain.” Proc Natl Acad Sci USA 93(3): 1156-60.
    Li, L., J. M. Olvera, et al. (2001). “Role of the non-homologous DNA end joining pathway in the early steps of retroviral infection.” EMBO J 20(12): 3272-81.
    Lombardo, A., P. Genovese, et al. (2007). “Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery.” Nat Biotechnol 25(11): 1298-306.
    Mani, M., J. Smith, et al. (2005). “Binding of two zinc finger nuclease monomers to two specific sites is required for effective double-strand DNA cleavage.” Biochem Biophys Res Commun 334(4): 1191-7.
    Miller, D. G., L. M. Petek, et al. (2004). “Adeno-associated virus vectors integrate at chromosome breakage sites.” Nat Genet 36(7): 767-73.
    Miller, J. C., M. C. Holmes, et al. (2007). “An improved zinc-finger nuclease architecture for highly specific genome editing.” Nat Biotechnol 25(7): 778-85.
    Modlich, U., J. Bohne, et al. (2006). “Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity.” Blood 108(8): 2545-53.
    Montini, E., D. Cesana, et al. (2006). “Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration.” Nat Biotechnol 24(6): 687-96.
    Nightingale, S. J., R. P. Hollis, et al. (2006). “Transient gene expression by nonintegrating lentiviral vectors.” Mol Ther 13(6): 1121-32.
    Ott, M. G., M. Schmidt, et al. (2006). “Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1.” Nat Med 12(4): 401-9.
    Perez, E. E., J. Wang, et al. (2008). “Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases.” Nat Biotechnol 26(7): 808-16.
    Porteus, M. H. and D. Carroll (2005). “Gene targeting using zinc finger nucleases.” Nat Biotechnol 23(8): 967-73.
    Schmidt, M., K. Schwarzwaelder, et al. (2007). “High-resolution insertion-site analysis by linear amplification-mediated PCR (LAM-PCR).” Nat Methods 4(12): 1051-7.
    Smith, T. F. and M. S. Waterman (1981). “Identification of common molecular subsequences.” J Mol Biol 147(1): 195-7.
    Szczepek, M., V. Brondani, et al. (2007). “Structure-based redesign of the dimerization interface reduces the toxicity of zinc-finger nucleases.” Nat Biotechnol 25(7): 786-93.


All references cited in this specification are herewith incorporated by reference with respect to their entire disclosure content and the disclosure content specifically mentioned in this specification.
The following Examples shall merely illustrate the invention. They shall not be construed, whatsoever, to limit the scope of the invention.



FIGURE LEGENDS
FIG. 1: Comparative analysis of off-site sequence homologies. The sequences of the 11 most likely off-site regions have been aligned using the sequence logo generator WebLogo (weblogo.berkeley.edu/).
FIG. 2: Insertion site distribution in K552 cells Coinfected with CCR5 targeting ZFN expressing IDLV and a donor IDLV containing homology regions to the target site., a) Genome wide location of IDLV identified by LAM-PCR. Blue triangles indicate distribution of 208 IS from two ZFN and donor IDLV treated samples, blue bars show location of IDLV integrants in a sample treated with the donor IDLV alone. b) Insertion sites located in Exon 3 of the CCR5 gene.
FIG. 3: Insertion site distribution in K562 cells coinfected with IL2RG targeting ZFN expressing IDLV and a donor IDLV containing homnology regions to the IL2RG target site. a) Genome wide location of IDLV identified by LAM-PCR. Red triangles indicate distribution of 96 IS from three GFP positive sorted samples, coinfected with ZFN expressing IDLV and donor IDLV. Red bars show the genomic locations of 37 IDLV IS in a sample treated with solely the donor IDLV. b) Location of the insertion sites in Exon 5 of the IL2RG gene.
FIG. 4: Number of IS into the same genomic region in ZFN treated cells. (a) Genomic regions which have been found to harbor multiple IS in the different cells treated with the CCR5 targeting ZFN are shown. (b) Regions with more than one Integration in IL2RG-ZFN treated cells. Percentages below the RefSeq gene name show the identity between the original ZFN target site and the off-target site.
FIG. 5. Comparison of off-site sequences of zinc finger motifs.



EXAMPLES
Example 1
IDLV Integration as a Stable Marker for DSB
To analyze whether IDLV are captured into preexisting DSB similar to what has been described for AAV derived vectors (Miller et al. 2004) and therefore can serve as a stable genetic marker for the temporary DSB, we introduced multiple DSB by gamma-irradiation in K562 cells and determined the frequency of integrated vector forms. K562 cells transduced with a GFP expressing IDLV prior to irradiation (48 hours after transduction) showed a frequency of GFP positive cells of 82.5% on day 5 after transduction, whereas non-irradiated cells revealed 68.7% GFP positive cells. 20 days after IDLV transduction 13.5% of the gamma-irradiated cells were still GFP positive, whereas only 6.2% of the non-irradiated cells showed GFP expression. These levels sustained for the whole observation period (35 days), an observation well in line with an increase in the frequency of IDLV integrations that are not diluted out by cell division (FIG. 1).
We analyzed the residual integration pattern of an IDLV carrying the D64V mutation in the viral integrase in transduced K562 cells (Donoru). Lentivirus integration sites (IS) of the IDLV in the cellular genome were studied by LAM-PCR (Schmidt et al. 2007) and nrLAM-PCR (Gabriel et al. 2009). Analysis of more than 100 IS from IDLVn transduced K562 cells (as well as  ̃500 IDLV IS obtained from other cell lines showed a close to random integration profile with no obvious preference of insertion into gene coding regions or other genomic structures of the human genome, contrary to what has been described for ICLV (FIG. 1). Small deletions (<24 bp) of the LTR were detectable in 20% of these sequences, which occurs only rarely in ICLV transduced cells. This may indicate that NHEJ is involved in IDLV insertions into DNA DSB.
Example 2
IDLV Marked DSB are Overrepresented in the Target Site after ZFN Application
To examine whether the integration pattern of IDLV changes after ZFN treatment, we analyzed IS in K562 cells infected with IDLV expressing ZFN either targeting Exon 3 of the CCR5 gene locus or Exon 5 of the IL2RG gene locus. These cells were co-infected with a non-integrating donor vector harboring a GFP expression cassette under control of the human PGK promoter, flanked by regions homologous to the respective target site (CCR5wt/hc or IL2RG1/hi, respectively). We had previously shown the targeted integration of the PGK-GFP expression cassette by HR in up to 50% in these cells (Lombardo et al. 2007).
We identified IDLV integrations by unbiased nrLAM and/or LAM-PCR optimized for accessing a large portion of the human genome by using the enzymes HpyCH4V, MseI, Tsp509I or MspI.
Deep sequencing of the amplified IDLV-genome junctions revealed 282 unique lentivirus LTR insertions in CCR5wt/hc samples. These IS were distributed throughout the genome (FIG. 2a) but strikingly, 59 out of these 282 IS (20.9%) could be mapped to Intron2 or Exon 3 of the CCR5 gene, located 1.4 kb to 2.7 kb up- or downstream of the ZFN target site (FIG. 2b). 30 of those 59 IS in the CCR5 gene were clustered at most 52 nucleotides apart from the ZFN binding site. These data indicate that IDLV integration at the specific ZFN target site resulted from NHEJ repair, which is known to introduce mainly small deletions of <60 bp, but also deletions up to 4 kb have been described (Honma et al. 2003; Honma et al. 2007).
Additionally, we analyzed the same ZFP fused to the recently described obligate heterodimeric Fokl nuclease domain (Miller et al. 2007). In cells treated with this advanced ZFN architecture, we detected 85 IDLV integrations in samples coinfected with the CCR5 homologous donor vector (CCR5muF/hc). Of those, 32 IS (37.6%) were located closer than 1.9 kb distance to the ZFN target site in the CCR5 gene, most of them (24 IS) within a 60 bp window surrounding the target site.
Insertion site analysis of cells transduced only with the IDLV donor vector harboring homologous sequences to the CCR5 target site (IDLVhc) in absence of the CCR5 targeting ZFN revealed 66 IS, 4 (6.1%) of them located within the CCR5 gene. These IS were located between 388 bp upstream and 988 bp downstream of the target locus, most likely representing spontaneous homologous recombination events (FIG. 2b).
In the case of the IL2RG1/hi approach, LAM PCR revealed 111 different genomic IDLV insertion loci, of which 13 (11.7%) mapped to the IL2RG locus, at most 1.1 kb apart from the ZFN target locus. Eight of these 13 IS were located within 16 bp distance to the ZFN target site (FIG. 3). Also here, we detected 3 out of 46 IS (6.5%) located in Intron 4 of the IL2RG gene, 235 to 611 bp downstream of the target site in one sample which has been treated with the IL2RG—homologous donor vector (IDLVhi) in absence of ZFN (FIG. 3b).
Example 3
Integration of IDLV into the CCR5 and IL2RG Target Site is Mediated by NHEJ
To analyze the proportion of ZFN induced off-target DSB more precisely, we sought to eliminate the possibility of HR competing with NHEJ. We repeated and expanded our analyses in K562 cells coinfected with CCR5- or IL2RG specific ZFN-expressing IDLV and a donor IDLV without any homology regions to either target site. Due to the lack of homology between donor IDLV and target locus, integration of the GFP expression cassette could not be attributed to HR. Therefore IDLV should be captured sequence independent into any DSB through NHEJ. (nr)LAM-PCR analysis of CCR5wt/n, samples showed 95 IS from which 29 (30.5%) mapped to the CCR5 locus. 26 of these IS were located closer than 55 bp apart from the ZFN target site.
Insertion site analysis of the samples treated with CCR5 specific ZFP fused to the mutated obligate heterodimeric Fokl nuclease domain revealed 290 IS in samples coinfected with the nonhomologous donor vector (CCR5muF/n). 71 (24.5%) of these IS were not exceeding 3.1 kb to the ZFN target site, whereas 52 IS were positioned within a 60 bp window surrounding the target site.
For the IL2RG targeting ZFN, we compared two different sets of zinc finger proteins. By (nr)LAM-PCR analysis we detected 208 IS in the IL2RG1/n setting, from which 17 IS (8.2%) mapped to the target locus. From the IL2RG2/n setting we retrieved 248 IS, from which 21 (8.5%) mapped to the target locus. These “on-target” IS were located at most at 585 bp distance to the site were the ZFN induced DSB is expected.
As a reminder, none of the IS obtained from the samples treated with the nonhomologous donor IDLV (IDLVn) alone was located in the vicinity to the CCR5 or IL2RG target site.
Example 4
Location of the Detected Off-Site Integration in ZFN Treated Cells
Out of the 377 unique IS retrieved from CCR5wt/hc and CCR5wt/n samples, on top of the 88 IS located within the CCR5 gene 80 additional IS were located in 13 different chromosomal regions, each of these loci carrying more than one integrated IDLV (FIG. 4). Such integrations with common locations have been found within the same sample but also between independently transduced cell populations. In some cases, the IDLV insertions were located in a very close distance to each other (0-60 bp), but also distances up to 260 bp between two IS have been found (FIG. 4a and Table 2).
In the samples transduced with the obligate heterodimeric Fokl ZFN (CCR5muF/hc and CCR5muF/n), 49 of the 375 IS identified by LAM-PCR have been found to be located in 7 other chromosomal loci separate from the CCR5 ZFN target site, each of them harboring at leastmore than 2 closely related IS (FIG. 4a and Table 2). Four of these loci, namely FLJ78302, KRR1, FBXL11 and ZCCHC14 have been found to harbor at least one IDLV integrant in the sample transduced with the mutated Fokl as well as the WT Fokl domain.
For the IL2RG1/hi and IL2RG1/n samples, we could identify 38 out of 318 IS in 15 genomic loci outside the target region, which itself harbored 30 IS. Each of these loci carried two to four IDLV insertions (Table 3). As integrations into such small regions are very unlikely to occur by chance, genomic loci which carry more than 1 IS in a very close proximity to each other may represent potential off-target hotspots for the respective ZFN.
Out of the 248 IS for the IL2RG2/n setting 32 IS were detected in 15 chromosomal loci, which harbored more than one IDLV integrant in close proximity. Three of these loci (FAM133B, SLC31A1 and SEC16A) harbored integrations in IL2RG1/n and IL2RG2/n samples and SEC16a had also an integration event in the IL2RG1/hi transduced cells (Table 3).
Example 5
Partial Target Sequence Homologies Determine the Likelihood of ZFN Induced DSB
We hypothesized that if ZFN target fidelity was substantial, off-target restriction of the ZFN should most likely affect the sequences of the genome most homologous to the original target motif. An in silico search of the human genome for possible off-target sites of ZFN action on the basis of sequence similarity to the intended target site of the ZFN heterodimer allowed to rank sequences most likely to be subject to cleavage by ZFN. As ZFN dimerization is most effective if the binding sites of the ZFN monomers are separated by 5-6 nucleotides, we searched for off-target binding sites allowing spacing of ZFN monomers between 0-10 nucleotides. In addition to the intended heterodimerization of two different ZEN monomers, we also searched for genomic sites supporting the formation of homodimers from each of the two ZFN monomers. The human genome does indeed contain numerous of these theoretical in silico off-target loci, which show only few mismatches to either target site. However, partial sequence homology is found to be more abundant for the CCR5 target site. Table 1 lists all genomic sites with partial homology to the ZFN target sites with at most two (CCR5) or three (IL2RG) mismatching nucleotides. From this top list with only minor differences to the target site, IDLV insertions have been detected in the ABLIM2 gene (4 IS) and in the CCR2/FLJ78302 gene (41 IS), both previously described known off-target sites of the CCR5 specific ZFN (Perez et al. 2008). These off-site motifs show 96 or 92% sequence similarity to the CCR5 target site, respectively. In case of the IL2RG specific ZFN, 2 IS had been detectable by LAM-PCR in the KIAA0528 gene (88% sequence homology to the target site). To determine the accuracy of our in silico modeling, we compared our data with the real IS identified by LAM PCR. Strikingly, we indeed found 150 IS in 66 loci where an integration event of the IDLV occurred within a 150 bp distance to a partially homologous ZFN target site, with more than 70.8% sequence similarity to the original CCR5 target site (Table 2). In cells treated with the IL2RG specific ZFN, 45 genomic loci with partial sequence homology to the target site carried 63 IDLV integrants in total (Table 3).
Example 6
Deep-Sequencing of Potential Off-Site Hotspots
To quantify the ZFN activity at the most likely off-site loci, we sequenced 15 genomic loci per ZFN target system by pyrosequencing after exposure to the different ZFN described above. These Loci were chosen based on the presence of a partial homologous target site in the vicinity of a identified IS or for the reason that more than 1 IS has been detected in this locus. After high-throughput sequencing of the amplified loci the obtained sequences have been analysed for signs of NHEJ, namely small insertions or deletions at these loci.
Example 7
In Vivo ZFN Binding Assay
To determine the sequence binding specificity of the different ZFP, we aligned the 11 most probable binding sites of the identified off target Loci. This comparative analysis of off-site sequence homologies allows to rapidly optimize zinc finger motifs (FIG. 5).
Example 8
Methods
γ-Irradiation of IDLV Transduced K562 Cells
1×104 K562 cells were seeded into a 12-well plate and transduced with a GFP expressing LV 24 h later with 0.6 μg HIV-1 gag p24. Cells have been γ-irradiated with 2.5 Gy 48 h after transduction. GFP expressing cells were counted by FACS for further 34 days.
Insertion Site Analysis by LAM-PCR.
To identify insertion sites of the IDLV LAM-PCR was performed as previously described using the enzymes Tsp509I, MseI, HpyCH4V and MspI (Schmidt et al. 2007). In brief, genomic DNA from transduced cell samples was preamplified by linear PCR using LTR-specific biotinylated primers. PCR products were captured on solid phase by magnetic beads (Dynabeads). After synthesis of the second strand, restriction digest of ds DNA and ligation of a linker cassette two additional rounds of exponential nested PCRs were performed. The resulting amplicons were sequenced using the Roche/454 platform and sequences obtained were aligned to the human genome via BLAT (BLAST like alignment tool) (Kent 2002)
Pyrosequencing Using the 454 Platform (Roche).
PSR amplicons were prepared as suggested by the manufacturer. An additional PCR (‘Fusionprimer-PCR’) with fusionprimers containing individual barcode sequences of 6 bases was carried out. 40 ng of purified LAM-PCR products served as template for the fusionprimer PCR reaction. PCR conditions: Initial denaturation 2 minutes at 95° C.; followed by 12 cycles at 95° C. for 45 s, 60° C. for 45 s and 72° C. for 60s. Final elongation was 5 minutes at 72° C. 15 μl of the PCR-products were analysed on a 2% agarose gel. DNA concentration was measured with the ND-1000 Spectrophotometer (Thermo Scientific).
IS Data Analysis of IDLV Transduced
LAM-PCR amplicon sequences have been identified through sequence alignment using BI2Seq (Altschul et al. 1990) and the Smith-Waterman algorithm (Smith and Waterman 1981; Gotoh 1982). After trimming, the sequences were aligned to the human genome using the assembly from UCSC (RefSeq genes and RepeatMasker; Alignment March 2006). IS were considered as valid if a LTR-genome junction was present and the flanking genomic region showed a unique sequence match of at least of 95% after alignment to the human genome using BLAT (Kent 2002)
In Silico Prediction of Off-Target Loci
In order to identify sequence parts homologous to the ZFN motives, the human genome was scanned for all possible 3mers contained in the ZFN motives. All matches were extended to full motive length depending on the location of the 3mer within the motive. Between the two ZFN cassettes a possible spacer from 0 to 10 nucleotides was considered. Consent was displayed in capital letters while mismatches with the ZFN motive were reported in lowercase. The information about the homologs was directly linked to the IS for further analyses.
TABLES







TABLE 1







Theoretical off-target hotspots based on sequence similarities to the ZFN binding


sites. Green hooks indicate an overlap between theoretical predicted off-site loci and








experimentally derived IS by LAM-PCR.





















Off-site


Identity


SEQ


Konfiguration
Chromosome
Locus
Target Sequence
Match
[%]
RefSeq

ID NO





ZFN-L_N5_ZFN-R
3
46389562
GTCATCCTCATCctgatAAACTGCAAAAG
24
100.0
CCR5
 
1


ZFN-L_N5_ZFN-L
4
8165389
GTCATCCTCATCtcacgGATGAGGATGcC
23
95.8
ABLIM2
 
2


ZFN-R_N6_ZFN-R
14
87308775
gTTTTGCAGTTTcacctcAAACTGCAAAAG
23
95.8
GALC

3


ZFN-L_N6_ZFN-R
3
46374223
GTCgTCCTCATCttaatAAACTGCAAAAa
22
91.7
FLJ78302/CCR2
 
4


ZFN-R_N6_ZFN-R
21
32319982
gTTTTGCtGTTTcagcttAAACTGCAAAAG
22
91.7
HUNK

5


ZFN-R_N6_ZFN-R
8
78368449
gTTTTGCtGTTTcacctaAAACTGCAAAAG
22
91.7
PXMP3

6


ZFN-R_N6_ZFN-R
17
64617769
CTTTTGCtGTTgcacctcAAACTGCAAAAG
22
91.7
ABCA6

7


ZFN-R_N8_ZFN-R
4
17039123
aTTTTGCAGTTTtgtcattcAAACTGCAAAtG
22
91.7
QDPR

8


ZFN-L_N7_ZFN-R
14
64097852
GTCATCCcCATCagggtacAAtCTGCAAAAG
22
91.7
C14orf50

9











Top off sites IL2RG


















Off-Site


Identity


SEQ


Konfiguration
Chromosome
Locus
Target sequence
Match
[%]
RefSeq

ID NO





ZFN-L_N5_ZFN-R
X
70245876
CTTCCACAGAGTgggttAAAGCGGCTCCG
24
100
IL2RG
 
10


ZFN-L_N4_ZFN-L
2
95716757
CTTCCACAGAGTgcctACTCTGTGtcAG
22
92
TRIM43

11


ZEN-L_N8_ZFN-L
6
51070975
CTTCCACAGAGTcatttcccgCTCTtcGGAAG
21
88
TFAP2B

12


ZFN-L_N8_ZFN-L
18
47472499
CTTCtACAGAGccggcgtacACTCTGTGGAtG
21
88
MEX3C

13


ZFN-L_N8_ZFN-L
10
133619910
CTTCCtCcGAGTccaggtggACTCTGTGGAtG
21
88
PPP2R2D

14


ZEN-L_N8_ZFN-L
6
169388271
CTTCCACAGAGTtttcaaacACTagGTGGAcG
21
88
THBS2

15


ZEN-L_N7_ZPN-L
9
125928116
CTTCCAgAGAGcaacccccACTCTtTGGAAG
21
88
LHX2

16


ZEN-L_N8_ZFN-L
12
113537261
CagCCAgAGAGTcactggtcACTCTGTGGAAG
21
88
TBX3

17


ZEN-L_N6_ZFN-L
2
188445229
CTTCCACtGtGTcctagaACTCTGTGcAAG
21
88
TFPI

18


ZEN-L_N7_ZFN-L
7
118347037
CTTCCACAGAGaaattccgACTCTcTGGAAa
21
88
ANKRD7

19


ZFN-L_N5_ZFN-L
11
127323200
CTTCCACAcAGTggtattCTCTaTGGAAG
21
88
ETS1

20


ZFN-L_N5_ZFN-L
12
22563143
CTTCCAtAtAGTtagagACTCTGTGGcAG
21
88
KIAA0528
 
21


ZFN-L_N4_ZFN-L
2
113803869
CTTCCACAGgGTgcctACTCTGTGtcAG
21
88
PAX8

22



























TABLE 2








Identify
OS



No. Of 

Distance to
SEQ 


RefSeq
Chr
Match
[%]
Locus
Configuration
Motif Sequence
Samples
IS
Region of IS
Motif
ID NO


























ABLIM2
4
23
95.8
8165391
L_5_L
GTCATCCTCATCtcacgGATGAGGATGcC
CCR5wt/hc-2;CCR5wt/n-1
4
8165369-8165401
2-22
140


FLI78302
3
22
91.7
46374224
L_5_R
GTCgTCCTCATCttaatAAACTGCAAAAa
CCR5muF/hc-1;CCR5muF/hc-2;
41
46374176-43674245
1-48
141









CCR5muF/n-1;CCR5muF/n-2;













CCR5muF/n-3;CCR5muF/hc-1;













CCR5muF/hc-2;CCR5wt/hc-3;













CCR5wt/hc-4;CCR5wt/n-1;













CCR5wt/n-2






MRPL22
5
21
87.5
154350452
L_5_L
aTCATCCTCATCttgcaGATGAGGgaGAC
CCR5wt/hc-4
1
154350453
2
23


VPS8
3
21
87.5
185963705
L_6_L
GTCATCCTCATCttcatccATGAGGAaGAg
CCR5muF/hc-1
1
185963805
100
24


VPS8
3
18
75.0
185963705
L_6_R
GTCATCCTCATCttcatccAtgaGgAAgAG
CCR5muF/hc-1
1
185963805
100
142


DDX10
11
20
83.3
108275348
R_5_R
CTTTTGCAtTTcaaaatAAACaGgAAAAG
CCR5wt/hc-1
1
108275350
3
25


KRR1
12
20
83.3
74249732
R_5_L
CaTTTcCAGTTTaaagaGATGAGGAgGcC
CCR5muF/hc-1;CCR5muF/n-3;
6
74249709-74249748
2-23
26









CCR5wt/hc-1;CCR5wt/n-2






PGC
6
20
83.3
41813540
R_5_R
CTgTTaCAGTTcacgagAAACTGCAAgAG
CCR5wt/hc-1;CCR5wt/hc-2;
6
41813533-41813551
1-12
27









CCR5wt/n-1






FAM27L
17
19
79.2
21807089
R_3_R
CTTTTtCAGTTTcccAAACTGaAActc
CCR5muF/n-3
1
21806997
92
28


FARP1
13
19
79.2
97605112
R_5_L
CTTTTGCAGTTTctgtgGgTGAGGActtt
CCR5wt/hc-2
1
97605115
4
29


FBLIM1
1
19
79.2
15970643
R_3_R
CTTTTGCAGTTTatgAAgCTGCAttct
CCR5wt/hc-2
1
15970643
1
30


GPR158
10
19
79.2
25432826
L_5_R
GTagTCCTCcTCctgctAAACTGCAAtgG
CCR5muF/hc-1
1
25432830
5
31


LPHN2
1
19
79.2
81568453
L_2_L
catcTCaTCATCatGATGAGGATGAC
CCR5wt/hc-2
1
81568446
7
32


MRPS9
2
19
79.2
105096447
R_5_R
CTTTTGCAGTTTagacaAAACTGCccggc
CCR5wt/hc-1
1
105096448
2
33


NEBL
10
19
79.2
21560894
R_10_L
CTTTTGCgGTTTatacacaactGATcAGcATtAg
CCR5wt/n-1
1
21560893
1
34


TBC1D4
13
19
79.2
74565440
L_5_L
aattTCCTCATCtgaaaGAcGAGGATGAC
CCR5wt/n-1
1
41565437
3
35


ACSF2
17
18
75.0
45851909
R_10_R
CTTTTaCAGTTTacaccaaaccAgAaTcaAAAAc
CCR5wt/n-2
1
45851903
6
36


C3orf56
3
18
75.0
128457777
R_4_R
CTTTTtCAGTTaattcAtctTGgAAAAG
CCR5wt/hc-1
1
128457779
2
37


IL1RAPL1
X
18
75.0
28670165
R_4_L
aTTTTGCAGTaTggaaaATGActATGcC
CCR5wt/n-1
1
28670265
100
38


JHDM1D
7
18
75.0
139454703
R_0_L
CcTTTGgtcTTTGATGAtGgTGAC
CCR5muF/n-1
1
139454799
96
39


KIAA0195
17
18
75.0
71002995
L_0_L
cTCcTCCTCATgGAgGAGGAgGgC
CCR5wt/hc-2
1
71002993
2
40


KSP37
10
18
75.0
46659554
L_5_R
GTtATCacCATCccaatAAACTGCAcAtt
CCR5wt/hc-2
1
44659667
114
41


MGAT4A
2
18
75.0
98606670
R_3_R
CgTTTGCAcTTTgtaAcACaGCAcAgG
CCR5muF/n-1
1
98606586
84
42


PKN2
1
18
75.0
88422189
R_7_R
gTTTatCAtTTctttatatAAACTGtAAAAG
CCR5wt/hc-1;CCR5wt/n-2
3
88422182-88422203
1-15
43


POU6F2
7
18
75.0
39226321
R_6_R
CacTTcCAGTTTattatgAAACcGtgAAAG
CCR5wt/n-2
1
39226320
1
44


TBC1D4
13
18
75.0
74848856
R_5_R
CTTTTaCAtTTctatagAAACaGtAAtAG
CCR5wt/hc-2
1
74848858
3
45


VEZT
12
18
75.0
94236444
R_5_R
CTcTTtCAGTTaagtagggACTGgAAAAG
CCR5wt/hc-1;CCR5wt/hc-3;
5
94236440-94236472
1-29
143









CCR5wt/n-1;CCR5wt/n-2






ADAMTSL1
9
17
70.8
18745601
R_5_R
CTTTTtCAGTTTttagggcACaGCcAtAt
CCR5muF/hc-1
1
18745598
3
47


AGBL1
15
17
70.8
84882294
L_8_L
GTtAaCCTCAgCtaggactgGATGttGcTGAt
CCR5muF/n-1
1
84882524
70
48


AKAP13
15
17
70.8
83950939
R_6_L
CTTTTcCgGTTTtgcctaGActgGGAaGAa
CCR5wt/n-1
1
83950935
4
49


ANXA8L2
10
17
70.8
47010363
R_5_L
CTTTTatAGaaattattGATGAGaATtAC
CCR5muF/n-1
1
47010351
12
50


C21orf70
21
17
70.8
45269125
R_6_L
CTTaTcCAGTcTatcatgGATGAGcATtca
CCR5muF/n-3
1
45269123
2
51


C9orf84
9
17
70.8
113545977
R_5_R
CTTTTaCAGTTgccaaacAAaTGgAAgtG
CCR5wt/hc-1
1
113545959
18
52


CCR2
3
17
70.8
46381746
L_4_R
GTCATCtTatTttaagAAAtTGCcAcAG
CCR5wt/n-2
1
46381717
29
53


CFHR5
1
17
70.8
195222427
R_8_R
ggTTTcCAGgTTcatccatgAccCTGCAAAgG
CCR5muF/n-2
1
19522285
142
54


CFLAR
2
17
70.8
201692281
L_10_L
GTCccCaTaAcCtcacaatgtgGtTGAGGAaGAC
CCR5wt/hc-2
1
201692282
1
55


CKS2
9
17
70.8
91114563
R_5_R
CTgTctCAcTTgttcagAAACcGgAAAAG
CCR5wt/hc-1
1
91114556
7
56


CMPK1
1
17
70.8
47586318
R_5_R
acaTTcCAGTTTagatgctAaTGCAAAAG
CCR5wt/n-1
1
47583628
11
57


CNTN1
12
17
70.8
39833854
R_5_R
CTTTTcacaTTTtaaagtAAgTGaAAAAG
CCR5muF/n-1
1
39833749
105
58


CPXR1
X
17
70.8
88089969
R_10_L
CTTTTaCAGTTcatagagaagaGtTGAGagTaAg
CCR5muF/n-3
1
88089969
0
59


EPHA3
3
17
70.8
88818701
R_6_R
CTTTTGgcaTTaaaaatatAACTtCAAAAa
CCR5muF/n-1
1
88818701
0
60


ETNK1
12
17
70.8
22675308
R_5_L
CcaTTaCAGTTTaaaaaGATGAGttaGAa
CCR5wt/hc-2
1
22675310
3
61


EXPH5
11
17
70.8
107965026
R_5_R
CTTTTcCAGgccacacaggACTGCAtAAG
CCR5wt/hc-3
1
107965019
7
62


FBXL11
11
17
70.8
66720371
R_5_L
CTaTTaCAGTTTtaagaGATGAGGtctca
CCR5muF/hc-1;CCR5muF/hc-2;
18
66720344-66720389
1-27
63









CCR5muF/n-1;CCR5muF/n-2













CCR5muF/n-3;CCR5wt/hc-1;













CCR5wt/hc-2;CCR5wt/hc-3;













CCR5wt/hc-4;CCR5wt/n-1;













CCR5wt/n-2






GLB1L2
11
17
70.8
133712023
R_3_R
CTTTTcCtGTTTatgAtgCTGtcAAtG
CCR5wt/hc-1
1
133712015
8
64


HMCN1
1
17
70.8
183767378
R_2_L
CTcTTcCAGTTTatGAgGAaGAgGtg
CCR5muF/n-3
1
183767381
3
65


IRF8
16
17
70.8
84608111
L_2_R
GgCcTCagGATCctcAACTGtAAAAt
CCR5wt/hc-1
1
84608107
4
66


LPP
3
17
70.8
189607262
R_10_R
CTcTgGCtGTTTttcttcccttAggCTGCtgAAG
CCR5wt/hc-2
1
189607402
140
67


MKI67
10
17
70.8
130093407
L_8_R
GTgATgCTCcgCagagtcgtAgACaGgAAAAG
CCR5wt/hc-1
1
130093511
104
68


MYOM3
1
17
70.8
24270059
L_4_R
ccCgTCCTCATCactgcAACaGCAAAa
CCR5wt/hc-2
1
24270061
2
69


NUP35
2
17
70.8
184157972
R_3_L
CTTTTGCccTTTcagtATGAtatTGgC
CCR5wt/hc-1
1
184157877
95
70


OLFM3
1
17
70.8
102275277
R_4_R
aTgTTtCccTTTtaagAAACTGCcAAAt
CCR5wt/hc-1
1
102275360
83
71


PLA2G4E
15
17
70.8
40059400
L_6_R
tTgATgCTCAgCagtagatAACTGgAAcAG
CCR5muF/n-3
1
40059399
1
72


PLCXD3
5
17
70.8
41357500
L_10_R
GTtATCCaaAcCaaaaagaacaAAACTGgAAgAa
CCR5muF/n-1
1
41357554
54
73


PPP3CA
4
17
70.8
102451010
R_6_R
CTTaTtCAaaTTaaataaAAACTatAAAtG
CCR5wt/hc-1
1
102451137
127
74


PSMA1
11
17
70.8
14557387
R_3_L
CTTcTGaAGgTTctaGAaGAGaATGct
CCR5muF/n-2
1
14557380
7
75


PTPN23
3
17
70.8
47393917
R_5_R
CTgTTcCAGcccatactgAACTGCAAcAG
CCR5wt/n-1
1
47393914
3
76


RPL22
1
17
70.8
6168296
R_5_R
CTTTTGCAtTactgtttgAAtTtCAgAAG
CCR5wt/hc-4
1
6168223
73
77


SETD4
21
17
70.8
36356367
R_5_R
CTTTTaCAGTTagatacAACTGgccAgc
CCR5wt/hc-1
1
36356364
3
78


SH3TC2
5
17
70.8
148432638
R_1_R
tTTTTtCAGTTTgAAtgaGCAgAgG
CCR5wt/hc-1
1
148432732
95
79


SIN3B
19
17
70.8
16834041
L_0_L
cTCATtCgCATCcATGAtGtTGAa
CCR5wt/hc-3
1
16833897
144
80


SOX9
17
17
70.8
67071530
R_9_L
CaaTTGCAGTTTtaccggctttATGtGaATGga
CCR5wt/hc-2
1
67071456
74
81


TBC1D16
17
17
70.8
75485496
R_3_R
gaTTTtCAGTTTtggAAAgattAAAAG
CCR5wt/hc-1
1
75485418
78
82


ZCCHC14
16
17
70.8
86056726
R_2_L
CTgTTaCAGTTTaaagaGAGGAgGcC
CCR5muF/hc-1;CCR5wt/hc-1;
9
86056724-86056739
2-13
83









CCR5wt/hc-2;CCR5wt/hc-4






ZCCHC6
9
17
70.8
88240282
R_5_R
CTTTTcCAcTcTtatgaAgAaaGaAAAAG
CCR5wt/hc-2
1
88240267
15
84


ZNF254
19
17
70.8
24366423
R_0_R
gcTTTGCAGccTAtAgTGgAAAAG
CCR5muF/n-1
1
24366557
134
85


SOS1
2
16
66.7
39202364
R_3_R
CTTTTGCgGTTctttcgACTagAtAAt
CCR5wt/hc-2;CCR5wt/n-1
3
39202367-39202376
4-13
86


C3orf59
3
16
66.7
194006348
R_5_R
CTTTTcCtaccacacatAAACTGgAAgAG
CCR5wt/hc-1;CCR5wt/hc-2;
6
194006325-194006350
3-23
87









CCR5wt/hc-2;CCR5wt/hc-4






PTGES2
9
16
66.7
129917964
L_5_L
caCccCCTCATCttacaGATGAGGAacct
CCR5wt/hc-2
2
129917964-129917966
1-3
88


PCDH9
13
16
66.7
63911404
R_1_L
tTTaTGCAcTTcatATGAGcATaAg
CCR5muF/n-1
2
63911341-63911481
63-78
89


ACSM5
16
16
66.7
20330794
R_5_R
CccTTcCAGTTgttcatcAACTGaAggAG
CCR5wt/hc-2
2
20330795-20330805
2-12
90


UQCRFS1
19
16
66.7
30536
L_5_R
GaCAgaaTCATtcccggAAACTGCgtAG
CCR5wt/hc-3;CCR5wt/n-3
2
32430290-32430544
9-246
91


TMEM77
1
15
62.5
111427840
R_7_R
tcTTTGgAGTTTgtaagtttAtaTGCAAtca
CCR5muF/n-1
2
111427843-111428070
4-231
92


FCGR1B
1
15
62.5
121185625
R_5_R
CTTgTGttGTgTgtattcAACTcacAgAG
CCR5muF/hc-1;CCR5muF/hc-2;
3
121185586-121185649
6-39
93









CCR5muF/n-1






FCGR1B
1
15
62.5
121186452
L_5_R
GaCAgaaTCATtcccacAAACTGCgttG
CCR5muF/hc-2;CCR5wt/hc-4
2
121186486

94


CCR2
3
15
62.5
46379384
R_2_L
tTTTTGttGTTgttGtTGttGtTtAC
CCR5wt/hc-1;CCR5wt/hc-2
—
46379064-46379301
83-320
95


UQCRFS1
19
15
62.5
32423943
R_5_R
CTTgTGttGTgTgtattcAACTcacAgAG
CCR5muF/n-1
2
32423939-32423947
4-5
144





(see previous page): Off-target sites in K562 cells treated with ZFN specific for CCR5. Correlation between experimentally identified IS and theoretical off-target loci, that harbor a partial sequence similarity to the CCR5 target site. Preferred IDLV integration sites are underlined in blue.
























TABLE 3
















SEQ



IS

Identity




No. Of

Distance
ID


RefSeq
Chr
Match
[%]
OS Locus
Configuration
Motif Sequence
Samples
IS
Region of IS
to Motif
NO


























KIAA0528
12
21
87.5
22563144
L_5_L
CTTCCAtAtAGTtagagACTCTGTGGcAG
IL2RG2/n-1
2
22563138-22563144
1-6
145


SLC36A1
5
20
83.3
150845074
L_5_L
CTgCCcCAGAGTatataACaCTGTGGcAG
IL2RG1/hi-1
1
150845075
2
96


ANXA5
4
19
79.2
122733977
R_5_L
tGcAGCCaCTTTttaaaACTCTtTGGcAG
IL2RG2/n-1
1
122733978
2
97


A26P1
16
18
75.0
7985881
L_5_R
CTgCCACAGRGTgctcaAcAcCGaCaCtG
IL2RG2/n-1
2
7985881-7985892
1-12
98


CLYBL
13
18
75.0
99364035
L_6_L
CTTCCtCAGAGggagcaagtgCTGgGGAAG
IL2RG1/hi-2
1
99364038
3
99


COL18A1
21
18
75.0
45651314
L_5_L
CTgCCcCAGccTcaagcACTCTGgGGcAG
IL2RG1/hi-2
1
45651310
4
100


FAM148B
15
18
75.0
60231561
L_1_R
CTTCCAtAGAGTagAAtCtGCcCCt
IL2RG2/n-1
1
60231567
7
101


GK5
3
18
75,0
143380386
L_5_R
CTgCCAaAtAGTttttcAAAGtGGCTCta
IL2RG2/n-1
1
143380377
9
102


LOC391343
2
18
75.0
868071
L_2_R
gTTCCtCAGAGTcctAAGgGGCTCaa
IL2RG2/n-1
1
868126
55
103


MGA
15
18
75.0
39782901
L_0_L
tcTCCAtattGTACTCTtTGGAAG
IL2RG2/n-1
1
39782912
11
104


NOMO2
16
18
75.0
18019661
R_6_L
tGGgGaCGCTTTctttgcACTCTtaGaAAG
IL2RG2/n-1
1
18019580
81
105


PTCHD2
1
18
75.0
11456399
L_5_L
CTgCCtCcGAGTactcaACTCgGTGGctG
112001/N-1
1
11456396
3
106


RADS1L1
14
18
75.0
67436348
L_9_L
CTTtacCAGAGTcacttggctAgTaaGTGGAAG
IL2RG1/n-1
1
67436353
6
107


SLC31A1
9
18
75.0
115023870
R_5_L
CctcGCCGCTTTcctcagCTCcGcGGAAG
IL2RG1/n-1;IL2RG2/n-1;
4
115023855-115023873
4-15
108









IL2RG1/hi-3






AP4S1
14
17
70.8
30623480
L_5_L
CTTCCAtttAGTggaaacCTCTGgtGcAG
IL2RG2/n-1
1
30623465
15
109


ARHGEF11
1
17
70.8
155222666
R_2_R
tGGAGgCtCTgTcaAAAGgGGCcCtG
IL2RG2/n-1
1
155222720
54
110


CENPC1
4
17
70.8
67948181
L_9_R
aTTCCACAaAaagagtgtttcAAAtCtGCTCtG
IL2RG1/hi-1
1
67948221
41
111


CTTNBP2NL
1
17
70.8
112620146
L_5_L
CTTCCtCcaAaacacagACTCTaaGGAAG
IL2RG2/n-1
1
112620143
3
112


DTWD2
5
17
70.8
117894727
L_7_L
CTTtgAacaAGTtttttaaACTCTGTtGAAc
IL2RG1/hi-1
1
117894800
74
113


EPHA7
6
17
70.8
94185716
L_4_R
CcTCCcCtGtGTgtgcAAAGCGGagCaG
IL2RG2/n-1
1
94185716
0
114


FAM19A1
3
17
70.8
68258713
R_8_R
CatAcCCGCTTTcaatacacAAAGgtGaTCtG
IL2RG1/n-1
1
68258581
132
115


FBXL2
3
17
70.8
33287060
L_6_L
CTTCCACAGgaTctgtgaACTCTtTcGgtc
IL2RG1/hi-2
1
33286929
131
116


HINT1
5
17
70.8
130386967
L_5_L
CTgCCtaAGAGTtagccctgCTcTGGAAG
IL2RG2/n-1
1
130386962
5
117


HLCS
21
17
70.8
37233561
R_5_R
tGGAcCCGCTTTtctcaAAgtgtGgTCCG
IL2RG1/n-1
I
37233552
9
118


HS6ST3
13
17
70.8
95977842
R_4_R
CaGAGCCtCTTgtagatAAGtGGgTCaG
IL2RG2/n-1
1
95977843
1
119


IFIT1
10
17
70.8
91142862
L_1_R
tTaCCACAGAGaaAAAGCaGgaCCc
IL2RG1/hi-3
1
91142790
72
120


KCTD8
4
17
70.8
43587881
L_5_R
gTTCCAgAcAGTggaatgAtGgGGCTCaG
IL2RG2/n-1
2
43587975-43587976
95-96
121


KIAA0355
19
17
70.8
39530643
L_6_L
CagaCcCAGAGTttgcacgCTaTGTGGcAG
IL2RG1/hi-3
1
39530645
2
122


KSP37
10
17
70,8
44637462
R_0_L
CaGAGCCcCTgcACTCaGaGGcAG
IL2RG2/n-1
1
44637467
5
123


MBTD1
17
17
70.8
46692505
L_1_L
CTTCCACcGtGggACcCTcTGcAgG
IL2RG2/n-1
1
46692491
14
124


NEB
2
17
70.8
152083108
R_5_R
tGtgGCCtCTTTtaggtgAAGCtGCTCCa
IL2RG2/n-1
1
152083177
70
125


OSBPL7
17
17
70.8
43244823
R_5_L
CaGAGCCtCcTggccatctcCTGTGGAAG
IL2RG1/hi-2
1
43244819
4
126


PCBD1
10
17
70.8
72329416
R_6_L
CGtAtCCaCTTccttatccCTtgGTGGAAG
IL2RG2/n-1
1
72329412
4
127


RAD9A
11
17
70.8
66922167
R_3_R
CGGtGCCGagactcccAAGCGGCTCtG
IL2RG1/hi-2
1
66922162
5
128


RRAS2
11
17
70.8
14273926
L_0_L
CTatCACAcAcTgCTtTGTGtAAG
IL2RG1/n-1
1
14273892
34
129


RRS1
8
17
70.8
67452086
R_4_L
gaGcGCCcCagTcactgCTCTGTGGAAG
IL2RG1/n-1
2
67452069-67452074
12-17
130


SCARB1
12
17
70.8
123822430
L_5_R
CTTCCcCAGttTaaaatcAAtCcaCTCCG
IL2RG1/n-1
3
123822426-123822444
3-15
131


SEC16A
9
17
70.8
138461130
R_6_L
CGtAcCCGCTcaccttgggCTCTGgGGcAG
IL2RG1/hi-1;IL2RG1/n-1;
4
138461051-138461132
1-79
132









IL2RG2/n-1






SF3B1
2
17

197957062
R_5_R
CtGAGCatCTTTgaactAAttCaGCTCtG
IL2RG2/n-1
4
197956936-197957142
8-126
133


SHROOM1
5
17
70.8
132193625
R_10_L
CaGAcCCGgTTacctggggttcAaTCTcTGGgAG
IL2RG1/hi-3
1
132193763
138
134


STAG1
3
17
70.8
137593393
L_5_L
CTgCCcCAGAGcttccaACTCTGgGaAtc
IL2RG1/hi-3;IL2RG1/n-1
4
137593389-137593400
4-8
135


SYNE2
14
17
70.8
63546096
L_6_R
aTctgcCAGAGTtatgttAAAGgGGCTCtG
IL2RG1/n-1
1
63546094
2
136


TOX2
20
17
70.8
42143811
R_8_L
aGGgtCCcCTcTcccacggccCTCTGgGGAAG
IL2RG1/n-1
1
42143939
128
137


TRIB1
8
17
70.8
126780005
R_5_L
CaaAGCCttgTccaaatACTCTGTGGcAG
IL2RG2/n-1
1
126779996
9
138


ZNF280D
15
17
70.8
54881712
L_5_R
CTgCCcttGAGTtttatAAAGgGGCTatG
IL2RG2/n-1
1
54881705
7
139





Off-target sites in K562 cells treated with IL2RG targeting ZFN. Correlation between experimentally identified IS and theoretical off-target loci, that harbor a partial sequence similarity to the IL2RG target site. Preferred IDLV integration sites are underlined in red.

## Claims

1. A method for determining the in vivo distribution of double-strand breaks induced by an endonuclease in a host cell, comprising:
a) incubating the host cell and a linear polynucleotide comprising a known sequence and encoding the endonuclease, wherein the linear polynucleotide comprising the known sequence and encoding the endonuclease is integrated into double-strand breaks in the genome in a sequence independent manner by non-homologous end joining;
b) detecting at least 50 in vivo insertion sites of the linear polynucleotide in the genome of the host cell by (i) amplifying polynucleotides from the genome using primers priming in the linear polynucleotide comprising the known sequence and (ii) determining at least one nucleic acid sequence which is in the genome and adjacent to the linear polynucleotide comprising the known sequence;
c) determining the in vivo positions of double-strand breaks based on the sequence information obtained in step b); and
d) determining the in vivo distribution of double-strand breaks induced by the endonuclease in the host cell.

2. The method of claim 1, wherein the linear polynucleotide is an integrase-deficient lentivirus.

3. The method of claim 1, wherein double-strand breaks are induced by a zinc-finger nuclease.

4. The method of claim 1, wherein the linear polynucleotide comprises an integrase-deficient lentivirus and encodes the zinc-finger nuclease.

5. The method of claim 1, wherein the insertion sites are detected by a method comprising PCR amplification followed by DNA sequencing.

6. The method of claim 5, wherein the PCR is LAM-PCR.

7. A method for determining the in vivo specificity of an endonuclease, comprising:
a) incubating a host cell comprising the endonuclease and a linear polynucleotide comprising a known sequence, wherein the linear polynucleotide comprising the known sequence is integrated into double-strand breaks in the genome in a sequence independent manner by non-homologous end joining;
b) detecting at least 50 in vivo insertion sites of the linear polynucleotide in the genome of the host cell by (i) amplifying polynucleotides from the genome using primers priming in the linear poiynucieotide comprising the known sequence and (ii) determining at least one nucleic acid sequence which is in the genome and adjacent to the linear polynucleotide comprising the known sequence;
c) determining the in vivo recognition sites of the endonuclease based on the sequence information obtained in step b); and
d) assessing the in vivo specificity of the endonuclease.

8. The method of claim 7, wherein the endonuclease is a Zinc-finger endonuclease.

9. The method of claim 7, wherein the linear polynucleotide is an integrase-deficient lentivirus.

10. The method of claim 7, wherein the insertion sites are detected by a method comprising PCR amplification followed by DNA sequencing.

11. The method of claim 10, wherein the PCR is LAM-PCR.

12. A method for obtaining an endonuclease with an altered in vivo specificity, comprising:
a) providing at least one mutant of an endonuclease with a known recognition sequence;
b) determining the in vivo specificity of the mutant of an endonuclease by a method comprising:
i) incubating a host cell comprising the endonuclease and a linear polynucleotide comprising a known sequence, wherein the linear polynucleotide comprising the known sequence is integrated into double-strand breaks in the genome in a sequence independent manner by non-homologous end joining;
ii) detecting at least 50 in vivo insertion sites of the linear polynucleotide in the genome of the host cell by (aa) amplifying polynucleotides from the genome using primers priming in the linear polynucleotide comprising the known sequence and (bb) determining at least one nucleic acid sequence which is in the genome and adjacent to the linear polynucleotide comprising the known sequence;
iii) determining the in vivo recognition sites of the endonuclease based on the sequence information obtained in step ii); and
iv) assessing the in vivo specificity of the endonuclease;

c) comparing the recognition sites recognized by the at least one mutant endonuclease with the recognition sites recognized by the unmodified endonuclease; and
d) obtaining an endonuclease with an altered in vivo specificity.

13. The method of claim 12, wherein the altered in vivo specificity is an increased in vivo specificity for a specific recognition sequence.

14. The method of claim 12, wherein the endonuclease is a Zinc-finger endonuclease.

15. The method of claim 1, wherein the determined position of the in vivo localization of double-strand breaks is within 5000 nucleotides from the position of double-strand breaks.